Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-POLARIS: NNC0487-0111 vs placebo in heart failure with preserved or mildly reduced ejection fraction and obesity
jRCT2031260113Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Modality
- Small Molecules, Peptides
01
Overview
Randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF), heart failure with mid-range ejection fraction (HFmrEF) and obesity comparing NNC0487-0111 with Placebo (2 arms). Primary endpoint: Primary composite heart failure endpoint. Started May 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)obesity
Beyond the preview
Go deeper on jRCT2031260113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260113.